For more than 30 years he has worked as executive R & D scientist and manager for
        major pharmaceutical companies in Germany and the USA in the field of
        immunology, biotherapeutics and associated disease areas, i.e. transplantation,
        autoimmune diseases and inflammatory disorders.

   As the leader of many R & D teams and projects he worked for companies like
        Behringwerke AG, Marburg,  Hoechst Marion Roussel Wiesbaden / Frankfurt, 
        Aventis Frankfurt / Bridgewater (New Jersey), and
        Sanofi-Aventis Bridgewater (New Jersey)/ Frankfurt.

   His responsibilities as manager, project team leader, project coordinator
        or scientific expert comprised internal and joint discovery and development
        programs in long-time collaborations with excellent, renowned biotech-
        or pharmaceutical companies, e.g.

     Immunex (now Amgen),

     Vertex,

     Millennium (now Takeda),

     Coley (now Pfizer),

     IntegratedGenetics (now Genzyme / Sanofi),

     Toyobo

     Pfizer

With these teams he has worked in many of the projects throughout the whole
R & D value chain, from discovery concept to late clinical development.
Many discovery projects reached clinical development or market.
 

Well recognized examples are

      Enbrel® (TNF-antagonist, for treatment of rheumatoid arthritis)

      monoclonal antibodies for immunosuppressive and immunoregulatory treatment
           in organ- and bone marrow transplantation and in autoimmune diseases

      recombinant and small molecule cytokine – inhibitors, generated by rational drug
           design for treatment of allergies and inflammatory diseases

      recombinant growth and differentiation factors, i.e.  IL-2, g-IFN, EPO; GM-CSF, 
           G-CSF  – for several indications, incl. oncology)

      recombinant and oral immunosuppressive drugs for prophylaxis and therapy in
           organ- and bone marrow transplantation, as well as for therapy of
           autoimmune diseases.

      Most recentl, he was project team leader for discovery of novel
           recombinant insulins with modified time-action profiles.

His work resulted in

   > 100 publications in national and international journals or books

   presentations at numerous national and international conferences

   > 15 patent applications / patent families

During his career he was a member of multiple strategy teams to evaluate business opportunities, competitive situations, internal and external opportunities, in-license opportunities, technologies, projects and commercial attractiveness of disease areas.

Dr. Kurrle is a member of several academic societies, e.g. the German Society of Immunology since 1976.